Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13144Neoplasms 10492Carcinoma, Non-Small-Cell Lung 6878Prostatic Neoplasms 6276Colorectal Neoplasms 5950Lung Neoplasms 5110Multiple Myeloma 3579Pancreatic Neoplasms 3564Leukemia, Myeloid, Acute 3512Neoplasm Metastasis 3511Carcinoma, Hepatocellular 3277Ovarian Neoplasms 3173Melanoma 3142Stomach Neoplasms 3058Lymphoma 2984Head and Neck Neoplasms 2608Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2500Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2317Lymphoma, Non-Hodgkin 2269Uterine Cervical Neoplasms 2193Rectal Neoplasms 2192Glioblastoma 2018Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1915Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1851Esophageal Neoplasms 1801

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER-2 Gene Amplification × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡